- Home
- CLPR vs ACET Comparison
CLPR vs ACET Comparison
Compare CLPR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | ACET |
|---|---|---|
| Founded | 2015 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1M | 69.6M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CLPR | ACET |
|---|---|---|
| Price | $3.18 | $7.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $65.33 |
| AVG Volume (30 Days) | 57.3K | ★ 161.1K |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 12.18% | N/A |
| EPS Growth | N/A | ★ 59.82 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,997,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $3.04 | $0.45 |
| 52 Week High | $4.68 | $9.05 |
Technical Indicators
Market Signals| Indicator | CLPR | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 57.76 |
| Support Level | $3.04 | $7.70 |
| Resistance Level | $3.96 | $8.46 |
| Average True Range (ATR) | 0.13 | 0.46 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 30.68 | 96.30 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.